ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF
This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
Latest Aventis Pharma S.A. Patents:
- Crystalline forms of dimethoxy docetaxel and methods for preparing the same
- Mutations of the parkin gene, compositions, methods and uses
- Crystalline form of cabazitaxel and process for preparing the same
- Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof
- MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USES
The present invention relates to combinations of a VEGF inhibitor and a chemotoxic agent of the class of 5-fluorouracil or 5-fluoropyrimidines that are useful in the treatment of neoplastic diseases.
VEGF inhibitors, which are inhibitors of vascular endothelial growth factor, are, in the majority of cases, biological products chosen from soluble receptors, antisenses, RNA aptamers and antibodies. The 5-fluoropyrimidine derivatives are chosen from 5-fluorouracil, capecitabine or gemcitabine, which exhibit notable antitumoral and antileukemia properties; they are particularly useful in the treatment of ovarian cancer, breast cancer, lung cancer or colon cancer. The present combination is directed in particular toward the treatment of colon cancer or stomach cancer.
The description and the preparation of the VEGF inhibitor preferably used in the invention, which is a VEGF-Trap chimeric protein, is described in patent application WO00/75319. There are several embodiments of the chimeric protein. The embodiment corresponding to VEGF-Trap is that described in FIG. 24 (sequence). The VEGF-Trap used in the invention is a fusion protein comprising the VEGFR1 signal sequence fused to the Ig domain D2 of the VEGFR1 receptor, itself fused to the Ig domain D3 of the VEGFR2 receptor, in turn fused to the Fc domain of IgG1, also called VEGFR1R2-FcΔC1 or Flt1D2.Flk1D3.FcΔC1.
In general, the doses used, which depend on factors specific to the individual to be treated, are between 20 and 800 micrograms per kilo when the administration is carried out subcutaneously and from 2 to 20 micrograms per kilo when the administration is carried out intravenously or, optionally, intranasally at a lower dose of the order of 0.01 picogram to 1 mg per kilo.
The 5-fluorouracil is generally used intravenously at a dose of between 500 mg/m2 and 5000 mg/m2 per week; as regards the 5-fluoropyrimidine derivatives such as capecitabine, they are generally used, for the latter, orally at a dose of between 500 and 3000 mg/m2 generally administered in two daily doses. Gemcitabine is generally used intravenously at a dose of between 500 and 2000 mg/m2 per week.
An article by H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, W Heim, J Berlin, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe, B Rogers, R Ross, F Kabbinavar published in “The New England Journal of Medicine” (N. Eng. J. Med. 350 (23) Jun. 3, 2004, 2335-2352) has described a clinical trial proving a better survival rate when the combination of bevacizumab with irinotecan, 5FU and leucovorin is used compared with the same combination containing no bevacizumab. Nothing proves, in this clinical trial, that the improvement in survival rate comes from the combination of 5FU with the bevacizumab; it may just as well come from the combination of irinotecan or of leucovorin with the bevacizumab, or may come from the quadruple combination. Now, as it is known that each of the anticancer agents brings, along with its therapeutic effect, toxic side effects, it appears to be opportune to limit their presence as much as possible, especially when the same effect can be obtained in the absence of at least one of them. In the present case, it is known that irinotecan leads to considerable diarrhea, which has sometimes led to the treatment having to be stopped. Furthermore, this article does not prove any synergistic effect within Corbett's meaning, i.e. an effect that cannot be obtained with each of the elements of the combination used alone at its maximum tolerated dose.
It has now been found, and it is this that forms the subject of the present invention, that the effectiveness of VEGF inhibitors can be considerably improved when they are administered in combination with at least one substance therapeutically useful in anticancer treatments that has a mechanism of action different from that of the VEGF inhibitors.
Moreover, since the activity of the products depends on the doses used, it is possible to use higher doses and to increase the activity by decreasing the phenomena of toxicity or delaying their appearance through the combination with the VEGF inhibitors or with their analogs of other therapeutically active substances, of growth factors of hematopoietic type, such as G-CSF or GM-CSF, or certain interleukins.
More particularly, the invention relates to the combinations of VEGF-Trap with 5-fluorouracil or derivatives thereof such as capecitabine or gemcitabine. It also relates to the combinations also including folinic acid generally combined with 5-FU.
The improved effectiveness of a combination according to the invention can be demonstrated by determining the therapeutic synergism.
A combination shows therapeutic synergism if it is therapeutically superior to one or other of the constituents used at its optimum dose [T. H. Corbett et al., Cancer Treatment Reports, 66, 1187 (1982)].
In order to demonstrate the effectiveness of a combination, it may be necessary to compare the maximum tolerated dose of the combination with the maximum tolerated dose of each of the individual constituents in the study under consideration. This effectiveness can be quantified, for example by the log10 of the killed cells, which is determined according to the following formula:
log10killed cells=T−C(days)/3.32×Td
in which T−C represents the delay in growth of the cells, which is the average time, in days, for the tumors of the treated group (T) and the tumors of the control group (C) to reach a predetermined value (1 g, for example) and Td represents the time, in days, required for the volume of the tumor to double in the control animals [T. H. Corbett et al., Cancer, 40, 2660.2680 (1977); F. M. Schabel et al., Cancer Drug Development, Part B, Methods in Cancer Research, 17 3-51, New-York, Academic Press Inc. (1979)]. A product is considered to be active if log10 killed cells is greater than or equal to 0.7. A product is considered to be very active if the log10 killed cells is greater than 2.8.
The combination, used at its own maximum tolerated dose, in which each of the constituents will be present at a dose generally less than or equal to its maximum tolerated dose, which show therapeutic synergy when the log10 killed cells is greater than the value of log10 killed cells of the best constituent when it is administered alone.
The effectiveness of the combinations on solid tumors can be determined experimentally in the following way:
30 to 60 mg of an MC 13/C mammary tumor fragment are transplanted bilaterally, subcutaneously, into the animals subjected to the experiment, generally mice, on day 0. The animals bearing the tumors are randomized before being subjected to the various treatments and controls. In the case of treatment of advanced tumors, the tumors are left to develop until the desired size, the animals having insufficiently developed tumors being eliminated. The animals selected are divided up randomly so as to undergo the treatments and the controls. Animals not bearing tumors can also be subjected to the same treatments as the tumor-bearing animals in order to be able to dissociate the toxic effect from the actual effect on the tumor. The chemotherapy generally begins from 3 to 22 days after the tumor transplant, according to the type of tumor, and the animals are observed every day. The various groups of animals are weighed three or four times a week until the maximum weight loss is obtained, and then the groups are weighed at least once a week until the end of the trial.
The tumors are measured two or three times a week until the tumor reaches approximately 2 g or until the animal's death if the latter occurs before the tumor reaches 2 g. The animals are autopsied when they are sacrificed.
The antitumor activity is determined as a function of the various parameters recorded.
To study the combinations on leukemias, a given number of cells are transplanted into the animals and the antitumor activity is determined by the increase in survival time of the treated mice compared with the controls. A product is considered to be active if the increased survival time is greater than 27% and it is considered to be very active if it is greater than 75% in the case of P388 leukemia.
By way of examples, the following tables give the results obtained with combinations of VEGF-Trap and 5-fluorouracile used at their optimum dose.
The present invention also relates to the pharmaceutical compositions containing the combinations according to the invention.
The products that constitute the combination can be administered simultaneously, separately or spread out over time so as to obtain the maximum effectiveness of the combination; it being possible for each administration to have a variable duration ranging from complete rapid administration to continuous infusion.
It results therefrom that, for the purpose of the present invention, the combinations are not only limited to those which are obtained by physical combination of the constituents, but also to those which allow a separate administration which may be simultaneous or spread out over time.
The compositions according to the invention are preferably compositions that can be administered parenterally. However, these compositions may be administered orally.
The compositions for parenteral administration are generally sterile pharmaceutically acceptable solutions or suspensions which may optionally be prepared extemporaneously at the time of use. For the preparation of nonaqueous solutions or suspensions, natural plant oils such as olive oil, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate can be used. The aqueous sterile solutions may consist of a solution of the product in water. The aqueous solutions are suitable for intravenous administration insofar as the pH is suitably adjusted and isotonicity is effected, for example by means of a sufficient amount of sodium chloride or glucose. The sterilization can be carried out by heating or by any other means that does not impair the composition. The combinations may also be in the form of liposomes or in the form of a combination with carriers such as cyclodextrins or polyethylene glycols.
In the combinations according to the invention, the application of these constituents may be simultaneous, separate or spread out over time, it is particularly advantageous for the amount of VEGF-Trap derivative to represent from 2 to 80% by weight of the combination, it being possible for this content to vary according to the nature of the substance combined, to the desired effectiveness and to the nature of the cancer to be treated.
“Pharmaceutically effective amount” is meant to describe an amount of the combinations according to the present invention, and constituents thereof, effective in producing the desired therapeutic effect. The constituents of the combinations according to the invention may be administered in dosages which are pharmaceutically effective for each constituent, or in dosages which are sub-clinical, i.e., less than pharmaceutically effective for each, or a combination thereof, provided that the combined dosages are pharmaceutically effective.
The combinations according to the invention are particularly useful in the treatment of colon and/or stomach cancers. In particular, they may have the advantage of being able to use the constituents at doses that are much lower than those at which they are used alone.
The following example illustrates a combination according to the invention.
EXAMPLEAmpoules of 1 cm3 containing 25 mg of VEGF-Trap, which are diluted in a phosphate buffer, are prepared, according to the usual technique, for subcutaneous administration.
0.2 ml per mouse is prepared, according to the usual technique, for intravenous administration, from a commercial solution of 5 cm3 containing 250 mg of 5 FU to be diluted with 5% glucose in water.
These solutions are administered simultaneously, after suitable dilution, by infusion.
The treatment can be repeated several times per day or per week until partial or complete remission or recovery.
Claims
1. A pharmaceutical composition comprising a pharmaceutically effective amount of a VEGF inhibitor and a pharmaceutically effective amount of 5-fluorouracil, and a pharmaceutically acceptable excipient.
2. A pharmaceutical composition comprising a pharmaceutically effective amount of a VEGF inhibitor and a pharmaceutically effective amount 5-fluoropyrimidine derivative, and a pharmaceutically acceptable excipient.
3. A method of treating a neoplastic disease, in a patient in need of such treatment, comprising administering to such patient a pharmaceutically effective amount of a combination of a VEGF inhibitor and 5-fluorouracil,
4. A method of treating a neoplastic disease, in a patient in need of such treatment, comprising administering to such patient a pharmaceutically effective amount of a combination of a VEGF inhibitor and a 5-fluoropyrimidine derivative.
5. A pharmaceutical composition according to claim 2 wherein the 5-fluoropyrimidine derivative is capecitabine or gemcitabine.
6. A method according to claim 4 wherein the 5-fluoropyrimidine derivative is capecitabine or gemcitabine.
7. A method according to either of claim 3 or 4, wherein the VEGF inhibitor is VEGF-Trap.
8. A pharmaceutical composition according to either of claims 1 or 2 wherein the VEGF inhibitor is VEGF-Trap.
9. A pharmaceutical composition according to claim 5 wherein the VEGF inhibitor is VEGF-Trap.
10. A method according to claim 6 wherein the VEGF inhibitor is VEGF-Trap.
11. A pharmaceutical composition according to either of claim 1 or 2, further comprising folinic acid.
12. A method according to either of claim 3 or 4, further comprising administering a pharmaceutically effective amount of folinic acid.
13. A method according to claim 3 wherein the VEGF inhibitor and 5-fluorouracil are administered simultaneously.
14. A method according to claim 3 wherein the VEGF inhibitor and 5-flourouracil are administered separately.
15. A method according to claim 4 wherein the VEGF inhibitor and the 5-fluoropyrimidine inhibitor are administered simultaneously.
16. A method according to claim 4 wherein the VEGF inhibitor and the 5-fluoropyrimidine inhibitor are administered separately.
17. A pharmaceutical composition according to claim 1 wherein the VEGF inhibitor is VEGF-Trap, and wherein the VEGF-Trap is present in the amount of 2% to 80% by weight of the total weight of VEGF-Trap and 5-fluorouracil.
18. A pharmaceutical composition according to claim 2 wherein the VEGF inhibitor is VEGF-Trap, and wherein the VEGF-Trap is present in the amount of 2% to 80% by weight of the total weight of VEGF-Trap and the 5-fluoropyrimidine derivative.
19. A method according to claim 3 wherein the VEGF inhibitor is VEGF-Trap, and wherein the VEGF-Trap is administered in an amount of 2% to 80% by weight of the total weight of VEGF-Trap and 5-fluorouracil.
20. A method according to claim 4 wherein the VEGF inhibitor is VEGF-Trap, and wherein VEGF-Trap is administered in an amount of 2% to 80% by weight of the total weight of VEGF-Trap and the 5-fluoropyrimidine derivative.
21. A pharmaceutical composition according to claim 1, further comprising folinic acid, provided that no other chemotoxic derivative is present, and which exhibits a therapeutically synergistic effect in the treatment of neoplastic disease.
22. A pharmaceutical composition according to claim 2, further comprising folinic acid, provided that no other chemotoxic derivative is present, and which exhibits a therapeutically synergistic effect in the treatment of neoplastic disease.
23. A method according to claim 3, further comprising administering a pharmaceutically effective amount of folinic acid, provided that no other chemotoxic derivative is administered, and wherein the amounts of the VEGF inhibitor, 5-fluorouracil and folinic acid administered exhibit a therapeutically synergistic effect in the treatment of the neoplastic disease.
24. A method according to claim 4, further comprising administering a pharmaceutically effective amount of folinic acid, provided that no other chemotoxic derivative is administered, and wherein the amounts of the VEGF inhibitor, the 5-fluoropyrimidine derivative and folinic acid administered exhibit a therapeutically synergistic effect in the treatment of the neoplastic disease.
25. Combinations containing a VEGF inhibitor with at least 5-fluorouracil or a 5-fluoropyrimidine derivative that is therapeutically useful in the treatment of neoplastic diseases.
26. Combinations containing a VEGF inhibitor with 5-fluorouracil or capecitabine or gemcitabine.
27. The combinations as claimed in claim 26, containing a VEGF inhibitor with fluorouracil.
28. The combinations as claimed in claim 27, containing a VEGF-Trap inhibitor with 5-fluorouracil.
29. The combinations as claimed in any one of claims 25 to 28, which also contain folinic acid.
30. The combinations as claimed in one of claims 25 to 28, which contain from 2 to 80% by weight of VEGF-Trap.
31. The combinations as claimed in claim 25, which also contain folinic acid, and which contain from 2 to 80% of VEGF-Trap.
32. The combinations as claimed in claim 26, which also contain folinic acid, and which contain from 2 to 80% of VEGF-Trap.
33. The combinations as claimed in claim 27, which also contain folinic acid, and which contain from 2 to 80% of VEGF-Trap.
34. The combinations as claimed in claim 28, which also contain folinic acid, and which contain from 2 to 80% of VEGF-Trap.
35. Products containing a VEGF inhibitor and at least one therapeutically useful substance as defined in one of claims 25 to 28, in the treatment of neoplastic diseases, as a combined preparation for simultaneous use, separate use or use spread out over time in anticancer therapy.
36. Products containing a VEGF inhibitor and at least one therapeutically useful substance as defined claim 25, and which may contain folinic acid, in the treatment of neoplastic diseases, as a combined preparation for simultaneous use, separate use or use spread out over time in anticancer therapy.
37. Products containing a VEGF inhibitor and at least one therapeutically useful substance as defined claim 26, and which may contain folinic acid, in the treatment of neoplastic diseases, as a combined preparation for simultaneous use, separate use or use spread out over time in anticancer therapy.
38. Products containing a VEGF inhibitor and at least one therapeutically useful substance as defined claim 27, and which may contain folinic acid, in the treatment of neoplastic diseases, as a combined preparation for simultaneous use, separate use or use spread out over time in anticancer therapy.
39. Products containing a VEGF inhibitor and at least one therapeutically useful substance as defined claim 28, and which may contain folinic acid, in the treatment of neoplastic diseases, as a combined preparation for simultaneous use, separate use or use spread out over time in anticancer therapy.
40. Combinations containing a VEGF inhibitor with at least 5-flurorouracil or a 5-fluoropyrimidine derivative and folinic acid with the exclusion of any other chemotoxic derivative exhibiting a therapeutically synergistic effect in the treatment of neoplastic diseases.
Type: Application
Filed: Mar 4, 2013
Publication Date: Jul 18, 2013
Applicants: Aventis Pharma S.A. (Antony), Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Inventors: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY), Aventis Pharma S.A. (Antony)
Application Number: 13/783,919
International Classification: A61K 31/513 (20060101); A61K 45/00 (20060101); A61K 31/519 (20060101); A61K 31/505 (20060101); A61K 38/18 (20060101); A61K 31/7068 (20060101);
